Docking 14 Million Virtual Isoquinuclidines against the μ and κ Opioid Receptors Reveals Dual Antagonists–Inverse Agonists with Reduced Withdrawal Effects
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Chemical Society
2025-04-01
|
| Series: | ACS Central Science |
| Online Access: | https://doi.org/10.1021/acscentsci.5c00052 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849719064644026368 |
|---|---|
| author | Seth F. Vigneron Shohei Ohno Joao Braz Joseph Y. Kim Oh Sang Kweon Chase Webb Christian B. Billesbølle Karthik Srinivasan Karnika Bhardwaj John J. Irwin Aashish Manglik Allan I. Basbaum Jonathan A. Ellman Brian K. Shoichet |
| author_facet | Seth F. Vigneron Shohei Ohno Joao Braz Joseph Y. Kim Oh Sang Kweon Chase Webb Christian B. Billesbølle Karthik Srinivasan Karnika Bhardwaj John J. Irwin Aashish Manglik Allan I. Basbaum Jonathan A. Ellman Brian K. Shoichet |
| author_sort | Seth F. Vigneron |
| collection | DOAJ |
| format | Article |
| id | doaj-art-a8f8651d36494ca6b0e29cb6047fdcc2 |
| institution | DOAJ |
| issn | 2374-7951 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | American Chemical Society |
| record_format | Article |
| series | ACS Central Science |
| spelling | doaj-art-a8f8651d36494ca6b0e29cb6047fdcc22025-08-20T03:12:12ZengAmerican Chemical SocietyACS Central Science2374-79512025-04-0111577079010.1021/acscentsci.5c00052Docking 14 Million Virtual Isoquinuclidines against the μ and κ Opioid Receptors Reveals Dual Antagonists–Inverse Agonists with Reduced Withdrawal EffectsSeth F. Vigneron0Shohei Ohno1Joao Braz2Joseph Y. Kim3Oh Sang Kweon4Chase Webb5Christian B. Billesbølle6Karthik Srinivasan7Karnika Bhardwaj8John J. Irwin9Aashish Manglik10Allan I. Basbaum11Jonathan A. Ellman12Brian K. Shoichet13Department of Pharmaceutical Chemistry, University of California, San Francisco, California, United StatesDepartment of Chemistry, Yale University, New Haven, Connecticut, United StatesDepartment of Anatomy, University of California, San Francisco, California, United StatesDepartment of Pharmaceutical Chemistry, University of California, San Francisco, California, United StatesDepartment of Chemistry, Yale University, New Haven, Connecticut, United StatesDepartment of Pharmaceutical Chemistry, University of California, San Francisco, California, United StatesDepartment of Pharmaceutical Chemistry, University of California, San Francisco, California, United StatesDepartment of Pharmaceutical Chemistry, University of California, San Francisco, California, United StatesDepartment of Anatomy, University of California, San Francisco, California, United StatesDepartment of Pharmaceutical Chemistry, University of California, San Francisco, California, United StatesDepartment of Pharmaceutical Chemistry, University of California, San Francisco, California, United StatesDepartment of Anatomy, University of California, San Francisco, California, United StatesDepartment of Chemistry, Yale University, New Haven, Connecticut, United StatesDepartment of Pharmaceutical Chemistry, University of California, San Francisco, California, United Stateshttps://doi.org/10.1021/acscentsci.5c00052 |
| spellingShingle | Seth F. Vigneron Shohei Ohno Joao Braz Joseph Y. Kim Oh Sang Kweon Chase Webb Christian B. Billesbølle Karthik Srinivasan Karnika Bhardwaj John J. Irwin Aashish Manglik Allan I. Basbaum Jonathan A. Ellman Brian K. Shoichet Docking 14 Million Virtual Isoquinuclidines against the μ and κ Opioid Receptors Reveals Dual Antagonists–Inverse Agonists with Reduced Withdrawal Effects ACS Central Science |
| title | Docking 14 Million Virtual Isoquinuclidines against the μ and κ Opioid Receptors Reveals Dual Antagonists–Inverse Agonists with Reduced Withdrawal Effects |
| title_full | Docking 14 Million Virtual Isoquinuclidines against the μ and κ Opioid Receptors Reveals Dual Antagonists–Inverse Agonists with Reduced Withdrawal Effects |
| title_fullStr | Docking 14 Million Virtual Isoquinuclidines against the μ and κ Opioid Receptors Reveals Dual Antagonists–Inverse Agonists with Reduced Withdrawal Effects |
| title_full_unstemmed | Docking 14 Million Virtual Isoquinuclidines against the μ and κ Opioid Receptors Reveals Dual Antagonists–Inverse Agonists with Reduced Withdrawal Effects |
| title_short | Docking 14 Million Virtual Isoquinuclidines against the μ and κ Opioid Receptors Reveals Dual Antagonists–Inverse Agonists with Reduced Withdrawal Effects |
| title_sort | docking 14 million virtual isoquinuclidines against the μ and κ opioid receptors reveals dual antagonists inverse agonists with reduced withdrawal effects |
| url | https://doi.org/10.1021/acscentsci.5c00052 |
| work_keys_str_mv | AT sethfvigneron docking14millionvirtualisoquinuclidinesagainstthemandkopioidreceptorsrevealsdualantagonistsinverseagonistswithreducedwithdrawaleffects AT shoheiohno docking14millionvirtualisoquinuclidinesagainstthemandkopioidreceptorsrevealsdualantagonistsinverseagonistswithreducedwithdrawaleffects AT joaobraz docking14millionvirtualisoquinuclidinesagainstthemandkopioidreceptorsrevealsdualantagonistsinverseagonistswithreducedwithdrawaleffects AT josephykim docking14millionvirtualisoquinuclidinesagainstthemandkopioidreceptorsrevealsdualantagonistsinverseagonistswithreducedwithdrawaleffects AT ohsangkweon docking14millionvirtualisoquinuclidinesagainstthemandkopioidreceptorsrevealsdualantagonistsinverseagonistswithreducedwithdrawaleffects AT chasewebb docking14millionvirtualisoquinuclidinesagainstthemandkopioidreceptorsrevealsdualantagonistsinverseagonistswithreducedwithdrawaleffects AT christianbbillesbølle docking14millionvirtualisoquinuclidinesagainstthemandkopioidreceptorsrevealsdualantagonistsinverseagonistswithreducedwithdrawaleffects AT karthiksrinivasan docking14millionvirtualisoquinuclidinesagainstthemandkopioidreceptorsrevealsdualantagonistsinverseagonistswithreducedwithdrawaleffects AT karnikabhardwaj docking14millionvirtualisoquinuclidinesagainstthemandkopioidreceptorsrevealsdualantagonistsinverseagonistswithreducedwithdrawaleffects AT johnjirwin docking14millionvirtualisoquinuclidinesagainstthemandkopioidreceptorsrevealsdualantagonistsinverseagonistswithreducedwithdrawaleffects AT aashishmanglik docking14millionvirtualisoquinuclidinesagainstthemandkopioidreceptorsrevealsdualantagonistsinverseagonistswithreducedwithdrawaleffects AT allanibasbaum docking14millionvirtualisoquinuclidinesagainstthemandkopioidreceptorsrevealsdualantagonistsinverseagonistswithreducedwithdrawaleffects AT jonathanaellman docking14millionvirtualisoquinuclidinesagainstthemandkopioidreceptorsrevealsdualantagonistsinverseagonistswithreducedwithdrawaleffects AT briankshoichet docking14millionvirtualisoquinuclidinesagainstthemandkopioidreceptorsrevealsdualantagonistsinverseagonistswithreducedwithdrawaleffects |